Anavo next stop for industry vet Shaun McNulty

Dutch firm Anavo Therapeutics, which claims to be the first company to systematically drug phosphatases, has named Shaun McNulty its chief scientific officer (CSO).

Dr McNulty, who has more than 30 years of experience in the biopharma industry and particular experience of designing and developing therapeutics in oncology, will oversee the implementation of Anavo’s strategy from discovery into clinical development.

"Anavo’s IGNITE platform uniquely enables the rapid identification and development of therapeutics targeting phosphatases, initially thought to be undruggable targets"Alongside newly-appointed senior vice president of chemistry and non-clinical development, Anna Quattropani and the wider management team, he will also oversee the continued design of Anavo’s first-in-class phosphatase-targeting allosteric modulators.